Trials / Recruiting
RecruitingNCT06361316
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 53 (estimated)
- Sponsor
- Kuirong Jiang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan liposome injection | Postoperative adjuvant therapy |
Timeline
- Start date
- 2024-04-08
- Primary completion
- 2025-03-25
- Completion
- 2028-07-31
- First posted
- 2024-04-11
- Last updated
- 2024-04-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06361316. Inclusion in this directory is not an endorsement.